Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited ( (AU:IMU) ) has shared an announcement.
Imugene Limited announced the issuance of 200 convertible notes and 526,315,789 warrants with an expiration date in January 2030. This issuance is part of previously announced transactions and highlights the company’s ongoing efforts to secure financial resources, which may bolster its capacity to advance its cancer immunotherapy projects.
More about Imugene Limited
Imugene Limited is a biotechnology company primarily focused on the development of cancer immunotherapies. The company works on innovative therapies that activate the immune system of cancer patients to improve their survival and quality of life.
YTD Price Performance: 8.33%
Average Trading Volume: 182,799
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $178.1M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.
